1er Consenso Uruguayo de Anticuerpos Antinucleares Departamento de Laboratorio Clínico, Unidad de Enfermedades Autoinmunes Sistémicas, Hospital de Clínicas Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Pasteur
{"title":"1er Consenso Uruguayo de Anticuerpos Antinucleares Departamento de Laboratorio Clínico, Unidad de Enfermedades Autoinmunes Sistémicas, Hospital de Clínicas Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Pasteur","authors":"Natalia Rodríguez, Celia Buzzi, E. Cairoli, Luís Eduardo Coelho Andrade, Ã. Danza, Cecilia Montenegro, Raquel Ballesté","doi":"10.29193/rmu.35.4.7","DOIUrl":null,"url":null,"abstract":"Antinuclear antibodies (ANA) are present in a large number of systemic autoimmune diseases (EAS), being a highly requested study in clinical practice, as well as a technique in high demand in clinical laboratories. Although in the last decade there has been a great regional and international effort to agree and standardize the test, in our country the laboratories show disparity in the techniques used and the initial dilution of screening. Likewise, in clinical practice, the indication of the test is often not well directed. In the Uruguayan Congress of Clinical Pathology of 2016, a Continuing Medical Education Course on the Use of ANA was given and once again the need to standardize both clinical and laboratory practices around the test was recognized. In order to generate a 1st Uruguayan Consensus on ANA, a working group was formed to discuss the issues to be agreed upon.","PeriodicalId":51931,"journal":{"name":"Revista Medica del Uruguay","volume":"20 2","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2019-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Medica del Uruguay","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29193/rmu.35.4.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Antinuclear antibodies (ANA) are present in a large number of systemic autoimmune diseases (EAS), being a highly requested study in clinical practice, as well as a technique in high demand in clinical laboratories. Although in the last decade there has been a great regional and international effort to agree and standardize the test, in our country the laboratories show disparity in the techniques used and the initial dilution of screening. Likewise, in clinical practice, the indication of the test is often not well directed. In the Uruguayan Congress of Clinical Pathology of 2016, a Continuing Medical Education Course on the Use of ANA was given and once again the need to standardize both clinical and laboratory practices around the test was recognized. In order to generate a 1st Uruguayan Consensus on ANA, a working group was formed to discuss the issues to be agreed upon.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
